Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 4, 2025
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI
Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026
Read more at globenewswire.comNASDAQ:EPRX (11/14/2025, 8:00:01 PM)
6.56
+0.22 (+3.47%)
Find more stocks in the Stock Screener
